Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis

Pediatric Pulmonology

Volumn 47, Issue 11, 2012, Pages 1113-1122

  Troxler, Robert Bradley ^a,b   Hoover, Wynton C ^a   Britton, Lacrecia J ^c   Gerwin, Andrea M ^d   Rowe, Steven M ^a,b,e,f  

^a University of Alabama at Birmingham and Children's Hospital   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c CHILDREN S HOSPITAL OF ALABAMA   (United States)

^d SAMFORD UNIVERSITY   (United States)

^e and Clinical Center   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

cystic fibrosis; eradication; mucoid; Pseudomonas aeruginosa; therapy

Indexed keywords

ANTIBIOTIC AGENT; TOBRAMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL GROWTH; BACTERIUM CULTURE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CYSTIC FIBROSIS; FEMALE; HUMAN; MALE; MUCOID PSEUDOMONAS AERUGINOSA INFECTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; SCHOOL CHILD;

ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HUMANS; LUNG; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECURRENCE; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES;

EID: 84867744034     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22543     Document Type: Article

References (32)

1. Welsh MJ, Ramsey BW, Accurso FJ, Cutting GR, Scriver CR, Beaudet AL,. Cystic fibrosis. In:, Scriver C, Sly W, Childs B, Beaudet A, Valle D, Kinzler K, Vogelstein B, editors. The metabolic and molecular basis of inherited diseases. New York, NY: McGraw-Hill; 2001. pp 5121-5188.
2. Strausbaugh S, Davis P,. Cystic fibrosis: A review of epidemiology and pathobiology. Clin Chest Med 2007; 28: 279-288.
3. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson R,. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100.
4. Rosenfeld M, Ramsey B, Gibson R,. Pseudomonas acquisition in young patients with cystic fibrosis: Pathophysiology, diagnosis, and management. Curr Opin Pulm Med 2003; 9: 492-497.
5. Burns J, Gibson R, McNamara S, Yim D, Emerson J, Rosenfeld M, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001; 183: 444-452.
6. Murray T, Egan M, Kazmierczak B,. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr 2007; 19: 83-88.
7. Li Z, Kosorok M, Farrell P, Laxova A, West S, Green C, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection, lung disease progression in children with cystic fibrosis. JAMA 2005; 293: 581-588.
8. Hentzer M, Teitzel G, Balzer G, Heydorn A, Molin S, Givskov M, et al. Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J Bacteriol 2001; 183: 5395-5401.
9. Hodges N, Gordon C,. Protection of Pseudomonas aeruginosa against ciprofloxacin and beta-lactams by homologous alginate. Antimicrob Agents Chemother 1991; 35: 2450-2452.
10. Ballmann M, Rabsch P, von der Hardt H,. Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax 1998; 53: 732-737.
11. Parad R, Gerard C, Zurakowski D, Nichols D, Pier G,. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun 1999; 67: 4744-4750.
12. Henry R, Mellis C, Petrovic L,. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992; 12: 158-161.
13. Gibson R, Emerson J, Mayer-Hamblett N, Burns J, McNamara S, Accurso F, et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 2007; 42: 610-623.
14. Douglas T, Brennan S, Gard S, Berry L, Gangell C, Stick S, et al. Acquisition,eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009; 33: 305-311.
15. Taccetti G, Campana S, Festini F, Mascherini M, Döring G,. Early therapy eradication against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005; 26: 458-461.
16. Frederiksen B, Koch C, Haiby N,. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23: 330-335.
17. Hansen C, Pressler T, Haiby N,. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008; 7: 523-530.
18. Haiby N, Frederiksen B, Pressler T,. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005; 4: 49-54.
19. Haiby N,. Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis. Paediatr Drugs 2000; 2: 451-463.
20. Koch C,. Early infection and progression of cystic fibrosis lung disease. Pediatr Pulmonol 2002; 34: 232-236.
21. Yoon S, Coakley R, Lau G, Lymar S, Gaston B, Karabulut A, et al. Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions. J Clin Investig 2006; 116: 436-446.
22. Gibson R, Emerson J, McNamara S, Burns J, Rosenfeld M, Yunker A, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 841-849.
23. McPherson H, Rosenthal M, Bush A,. Can mucoid Pseudomonas aeruginosa be eradicated in children with cystic fibrosis? Pediatr Pulmonol 2010; 45: 566-568.
24. Bjarnsholt T, Jensen PA, Jakobsen TH, Phipps R, Nielsen AK, Rybtke MT, et al. Quorum sensing,virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis patients. PLoS ONE 2010; 5: e10115.
25. Farrell P, Rosenstein B, White T, Accurso F, Castellani C, Cutting G, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008; 153: S4-S14.
26. Lee T, Brownlee K, Conway S, Denton M, Littlewood J,. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003; 2: 29-34.
27. Troxler R, WHoover W, Britton L, Gerwin A, Rowe S,. Eradication of mucoid Pseudomonas aeruginosa in patients with cystic fibrosis: A retrospective analysis. 23rd Annu North Am Cyst Fibros Conf 2009; 9: S32-S327
28. Nixon G, Armstrong D, Carzino R, Carlin J, Olinsky A, Robertson C, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001; 138: 699-704.
29. Levy H, Kalish L, Cannon C, Garca K, Gerard C, Goldmann D, et al. Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients. Pediatr Pulmonol 2008; 43: 463-471.
30. Gutierrez J, Grimwood K, Armstrong D, Carlin J, Carzino R, Olinsky A, et al. Interlobar differences in bronchoalveolar lavage fluid from children with cystic fibrosis. Eur Respir J 2001; 17: 281-286.
31. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999; 28: 321-328.
32. Rodriguez-Rojas A, Oliver A, Blazquez J,. Intrinsic and environmental mutagenesis drive diversification and persistence of Pseudomonas aeruginosa in chronic lung infections. J Infect Dis 2012; 205: 121-127.